Related Experiment Video
Updated: Dec 25, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Peritoneal mesothelioma
Alissa Greenbaum1, H Richard Alexander1
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Abstract:
Malignant peritoneal mesothelioma (MPM) is a rare and lethal disease of the peritoneal lining, with high variability in biologic aggressiveness. Morbidity and mortality of the disease are related to progressive locoregional effects within the abdominal cavity, such as distention, pain, early satiety, and decreased oral intake that can ultimately lead to bowel obstruction and cachexia. The standard of care for patients with resectable disease remains cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), with potential survival outcomes greater than 5 years in appropriately selected patients. Patients with inoperable MPM can be offered systemic treatment, although the disease is usually refractory to standard chemotherapic regimens. Patients with MPM should be treated at high volume centers with strong consideration for inclusion in tumor registries and clinical trials. In 2020, research will continue to explore promising genetic and immunologic targets and focus on refinement of surgical methods to optimize CRS-HIPEC approaches.
Insights
Malignant peritoneal mesothelioma (MPM) is a rare cancer. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) offer survival benefits for resectable cases, while inoperable disease requires further research.
Area of Science:
- Oncology
- Surgical Oncology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer of the peritoneum.
- Disease progression causes significant morbidity, including bowel obstruction and cachexia.
- Treatment options are limited, especially for inoperable cases.
Purpose of the Study:
- To review the current standard of care for MPM.
- To highlight the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).
- To discuss challenges and future research directions for MPM treatment.
Main Methods:
- Review of existing literature and treatment guidelines for MPM.
- Analysis of outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).
- Discussion of systemic treatment limitations and emerging therapeutic targets.
Main Results:
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can achieve >5-year survival in selected patients with resectable MPM.
- MPM is often refractory to standard systemic chemotherapy regimens.
- High-volume centers and clinical trial participation are crucial for optimal patient management.
Conclusions:
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard of care for resectable MPM.
- Further research into genetic/immunologic targets and surgical refinement is essential for improving outcomes in inoperable MPM.
- Multidisciplinary care at specialized centers is recommended for MPM patients.
Related Concept Videos
Pleural Disorders: Types and Brief Description
Peritoneum
Anatomy of the Peritoneum
The peritoneum is divided into two layers: the parietal peritoneum and the visceral...
Pleura of the Lungs
Esophageal Perforation-I: Introduction
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

